Karo Pharma AB (Karo Pharma AB) Total Stockholders Equity : $822.9 Mil (As of Jun. 2022)

View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Total Stockholders Equity?

Karo Pharma AB's Total Stockholders Equity for the quarter that ended in Jun. 2022 was $822.9 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Karo Pharma AB's Book Value per Share for the quarter that ended in Jun. 2022 was $3.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Karo Pharma AB's Debt-to-Equity for the quarter that ended in Jun. 2022 was 1.06.

Karo Pharma AB Total Stockholders Equity Historical Data

The historical data trend for Karo Pharma AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Total Stockholders Equity Chart

Karo Pharma AB Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Stockholders Equity

Get a 7-Day Free Trial

189.04

399.87

597.97

673.92

639.35

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
Total Stockholders Equity	Get a 7-Day Free Trial															676.80	693.22	680.70	639.35	822.87

Karo Pharma AB (OTCPK:KARBF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Karo Pharma AB's Book Value per Share for the quarter that ended in Jun. 2022 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(822.868	-	0)	/	273.255
	=	3.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Karo Pharma AB's Debt-to-Equity for the quarter that ended in Jun. 2022 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.473	+	859.57)	/	822.868
	=	1.06

Karo Pharma AB Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (Karo Pharma AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22

Website

https://www.karopharma.com

Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire • 06-25-2019